AstraZeneca aims to transform the oncology treatment landscape with diverse early pipeline and novel combinations at AACR
Clinical data in immuno-oncology and DNA damage response illustrate potential of next-wave medicines to advance cancer care.First data for novel molecules show promising anti-cancer activity and showcase strategy to attack cancer from multiple angles.AstraZeneca will present new data underscoring the breadth of the Company’s early oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, 8 to 13 April 2022. Data from 60 presentations, including 5 oral and 3 mini-oral presentations, will feature the Company’s next wave of potential cancer